Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
NCT02184572
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Lincoln, Nebraska +3 locations
Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
NCT03207750
Completed
The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
12/07/2020
Locations: GSK Investigational Site, Lincoln, Nebraska +2 locations
Conditions: Rotavirus Infection, Rotavirus Vaccines
Register for Updates
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Completed
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
09/10/2018
Locations: Not set, Lincoln, Nebraska +2 locations
Conditions: Meningococcal Disease, Meningococcal Meningitis
Register for Updates
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
NCT02868073
Completed
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/29/2018
Locations: Celerion, Inc., Lincoln, Nebraska
Conditions: Norovirus Gastroenteritis
Register for Updates
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
NCT03125473
Completed
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
Gender:
ALL
Ages:
Between 19 years and 49 years
Trial Updated:
05/29/2018
Locations: Celerion, Inc., Lincoln, Nebraska
Conditions: Norovirus Gastroenteritis
Register for Updates
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
NCT01424644
Completed
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by these vaccines when given alone.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
01/21/2014
Locations: Bellevue Family Practice, 2206 Longo Suite 201, Bellevue, Nebraska +2 locations
Conditions: Meningococcal Meningitis
Register for Updates